Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126823782 | 12682378 | 2 | F | 20160825 | 20160825 | 20160831 | EXP | BE-ROCHE-1817669 | ROCHE | 0.00 | F | Y | 40.80000 | KG | 20160831 | MD | BE | BE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126823782 | 12682378 | 1 | PS | HERCEPTIN | TRASTUZUMAB | 1 | Intravenous (not otherwise specified) | 103792 | 4 | MG/KG | SOLUTION FOR INFUSION | ||||||||
| 126823782 | 12682378 | 2 | SS | LEUCOVORIN CALCIUM. | LEUCOVORIN CALCIUM | 1 | Intravenous (not otherwise specified) | U | 0 | ||||||||||
| 126823782 | 12682378 | 3 | SS | LEUCOVORIN CALCIUM. | LEUCOVORIN CALCIUM | 1 | Intravenous (not otherwise specified) | ON 14/JUN/2016, SHE RECEIVED OF MFOLFOX | U | 0 | |||||||||
| 126823782 | 12682378 | 4 | SS | FLUOROURACIL. | FLUOROURACIL | 1 | Intravenous (not otherwise specified) | ON 14/JUN/2016, SHE RECEIVED LAST DOSE OF MFOLFOX?INTERRUPTED ON 22/MAR/2016 | U | 0 | |||||||||
| 126823782 | 12682378 | 5 | SS | FLUOROURACIL. | FLUOROURACIL | 1 | Intravenous (not otherwise specified) | ON 14/JUN/2016, SHE RECEIVED MFOLFOX | U | 0 | |||||||||
| 126823782 | 12682378 | 6 | SS | OXALIPLATIN. | OXALIPLATIN | 1 | Intravenous (not otherwise specified) | INTERRUPTED ON 22/MAR/2016?ON 14/JUN/2016, SHE RECEIVED LAST DOSE OF MFOLFOX | U | 0 | |||||||||
| 126823782 | 12682378 | 7 | SS | OXALIPLATIN. | OXALIPLATIN | 1 | Intravenous (not otherwise specified) | ON 14/JUN/2016, SHE RECEIVED MFOLFOX | U | 0 | |||||||||
| 126823782 | 12682378 | 8 | C | BETAMETHASONE. | BETAMETHASONE | 1 | Unknown | 2X4MG FOR FETAL LUNG MATURATION | 0 | ||||||||||
| 126823782 | 12682378 | 9 | C | ALOXI | PALONOSETRON HYDROCHLORIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126823782 | 12682378 | 1 | Adenocarcinoma gastric |
| 126823782 | 12682378 | 2 | Adenocarcinoma gastric |
| 126823782 | 12682378 | 4 | Adenocarcinoma gastric |
| 126823782 | 12682378 | 6 | Adenocarcinoma gastric |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126823782 | 12682378 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126823782 | 12682378 | Deep vein thrombosis | |
| 126823782 | 12682378 | Maternal exposure during pregnancy | |
| 126823782 | 12682378 | Premature labour |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126823782 | 12682378 | 1 | 201501 | 20160322 | 0 | |
| 126823782 | 12682378 | 2 | 201501 | 20160322 | 0 | |
| 126823782 | 12682378 | 3 | 20160330 | 20160628 | 0 | |
| 126823782 | 12682378 | 4 | 201501 | 20160322 | 0 | |
| 126823782 | 12682378 | 5 | 20160330 | 20160628 | 0 | |
| 126823782 | 12682378 | 6 | 201501 | 20160322 | 0 | |
| 126823782 | 12682378 | 7 | 20160330 | 20160628 | 0 |